Springer Nature, a world-leading research, educational, and professional publisher, has partnered with Seegene Inc., a South Korean company specializing in PCR molecular diagnostics, as a strategic partner in their OneSystem™ Business. The partnership aims to expand the reach of Seegene's syndromic quantitative PCR technology and knowledge through collaboration with scientists worldwide.
Seegene's OneSystem™ Business is dedicated to providing scientists with the tools and expertise to develop customized products tailored to local needs. By leveraging its unique syndromic PCR technology, Seegene aims to contribute to a disease-free world, targeting various diseases such as cancer and infectious diseases in humans and other organisms. Recently, Seegene has established partnership agreements with leading diagnostic companies in Israel and Spain as part of their OneSystem™ Business initiative.
The strategic partnership with Springer Nature is based on a shared vision of fostering collaboration among scientists to drive innovative solutions. With the active support of Springer Nature, Seegene's OneSystem™ Business will have a broader impact on global communities. Springer Nature will introduce the OneSystem™ Business initiative to the global scientific community, encouraging scientists and experts from around the world to participate in the development of new assays through Seegene's collaborative network.
The initial step of collaboration between Seegene and Springer Nature will be the launch of the OneSystem Project in the second half of 2023. The project aims to develop 20 syndromic PCR assays in collaboration with scientists worldwide. Springer Nature will facilitate the selection and evaluation of potential participants for the PCR reagent development project, with plans to initiate assay development the following year.
In the long term, Seegene and Springer Nature have ambitious plans to establish an enhanced project proposal system, aiming to increase the number of developed assays to hundreds and thousands per year. This collaborative approach is crucial, as a typical PCR molecular diagnostic company can independently develop only a limited number of syndromic assays annually.
With this strategic partnership, Seegene and Springer Nature are poised to make significant strides in advancing molecular diagnostics and fostering collaboration in the scientific community, ultimately contributing to improved global health outcomes.
Click here to read the original press release.
